featured
Decitabine Plus Anti–PD-1 Camrelizumab in Patients With Hodgkin Lymphoma Who Progressed or Relapsed After PD-1 Blockade Monotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Decitabine Plus Anti-PD-1 Camrelizumab in Patients With Hodgkin Lymphoma Who Progressed or Relapsed After PD-1 Blockade Monotherapy
Clin. Cancer Res 2021 Mar 05;[EPub Ahead of Print], C Wang, Y Liu, L Dong, X Li, Q Yang, MV Brock, Q Mei, J Liu, M Chen, F Shi, M Liu, J Nie, W HanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.